Chewy (CHWY) Teardown: The Autoship Profit Engine

$12.6 billion in revenue. $562 million in free cash flow. And a gross margin that has ground 60-80 basis points higher every year for the last three years. That is Chewy in FY2025 (fiscal year ended February 1, 2026).

It is tempting to call this a growth story. The correct read is a profitability inflection - a business that spent years burning cash to acquire the customer base that now funds its own expansion. The Autoship subscription program, at 83.3% of net sales, has converted a commodity pet-supply retailer into something closer to a recurring-revenue platform. FCF of $8.6M in FY2021 compounding to $562.4M by FY2025 is not a rounding error.

What makes this more interesting than a straight upgrade is the emerging tension: top-line growth is slowing, the clinic bet is capital-intensive with no disclosed unit economics, and the company that perfected subscription e-commerce is now trying to build a veterinary chain. That is the teardown.

Section 1 - The snapshot

Metric	FY2025	Q1 FY2026	Q1 FY2025 (prior year)
Revenue	$12,601.5M	$3,357.2M	$3,116.0M
Revenue YoY	+6.2% (+8.3% normalized)	+7.7%	+8.3%
Gross margin	29.8%	30.1%	29.6%
Operating income (margin)	$254.3M (2.0%)	$128.5M (3.8%)	$76.9M (2.5%)
Adjusted EBITDA (margin)	$719.2M (5.7%)	$253.1M (7.5%)	n/a
Free cash flow	$562.4M	$70.8M (Q1)	n/a
Net income (GAAP)	$222.8M	$94.8M	$62.4M
Cash + securities	$878.8M	$485.2M	n/a
Total funded debt	$0	$0 (ABL undrawn)	$0
Autoship % of net sales	83.3%	84.4%	~82%
Active customers	21.327M	21.497M	~20.6M
NSPAC	$591	$597	n/a

The five-year arc:

Fiscal year	Revenue	YoY	Gross margin	Operating margin	FCF	Autoship % of sales	NSPAC
FY2021 (ended Jan 30, 2022)	$8,967M	n/a	~27.5%*	n/a*	$8.6M	70.5%	$434
FY2022 (ended Jan 29, 2023)	$10,119M	+12.8%	~26.6%*	n/a*	$119.3M	73.2%	$496
FY2023 (ended Jan 28, 2024)	$11,148M	+10.2%	28.4%	-0.2%	$342.9M	76.2%	$555
FY2024 (ended Feb 2, 2025)	$11,861M	+6.4%	29.2%	0.9%	$452.5M	79.2%	$578
FY2025 (ended Feb 1, 2026)	$12,602M	+6.2%	29.8%	2.0%	$562.4M	83.3%	$591

Section 2 - The business model: how they actually make money

Chewy is a pure-play direct-to-consumer e-commerce retailer - no physical store fleet, no Amazon Marketplace presence, no wholesale channel. The 10-K FY2025 describes it as "primarily an e-commerce business geared toward pet products and services," selling through "retail websites, and its mobile applications." One operating segment, one channel, seventeen fulfillment centers across the United States.

The revenue structure breaks into four categories: Consumables (pet food and treats, $8,777.9M, 69.7% of FY2025 net sales), Pet health and specialty products including pharmacy and vet care ($1,980.5M, 15.7%), Hardgoods such as toys, beds, and crates ($1,436.3M, 11.4%), and Other ($406.8M, 3.2%). Source: 10-K FY2025.

Where does the 29.8% gross margin come from in a thin-margin category? Three levers. First, the Autoship subscription program compresses promotional frequency: recurring orders carry less promotional discount than one-off purchases, which lifts realized gross margin on the same product mix. Second, the private-label portfolio - American Journey and Tylee's in consumables, Frisco in hardgoods, Vibeful in wellness - carries higher margin than national brands. Third, and most important for the forward thesis, pharmacy (included in the pet health and specialty category) is the highest-margin product type Chewy sells and grew 13.3% in Q1 FY2026 versus 5.3% for consumables. Chewy describes itself as the #1 pet pharmacy in America and operates the PracticeHub platform for veterinarians, which generates a software/referral layer on top of fulfillment.

Here is what that model looks like in the hands of customers. These videos are demand-culture signals, not load-bearing financial facts.

@jonathan.roehm

Restock with Chewy! Check out @Chewy for all of your pet needs! #chewypartner #chewy

♬ LENS FLARE - Louis La Roche

@jonathan.roehm, 1.5M plays, 1,963 likes. The demand signal: high-reach pet creators treating Chewy as the default restock channel. Social signal only.

@cam2rs.cats

Our cats are high maintenance. Luckily @Chewy has our back 🐱💙 #ChewyPartner #Ad

♬ original sound - Cat2r

@cam2rs.cats, 391.8K plays, 24K likes. Cat-parent loyalty to the Chewy brand at scale. Social signal only.

@salemandharry

I usually try to order food in bulk and through autoship because of the small discount :) #catsoftiktok #catfoodcost #feedmycat #catmeals #catasmr

♬ love nwantinti (ah ah ah) - CKay

@salemandharry, 174.1K plays, 13.8K likes. The consumer behavior the Autoship model is built on: habitual bulk ordering on subscription to save money. Social signal only.

Section 3 - Strengths: the moat that is real

1. An Autoship mix so deep it functions like a subscription P&L. Autoship customer sales reached $10,497.1M in FY2025 - 83.3% of total revenue. In Q1 FY2026 it ticked to 84.4% ($2,832.6M out of $3,357.2M). No US pet retailer discloses a comparable recurring-revenue mix - and unlike a curated subscription box such as BARK, whose order count can collapse even as per-box gross margin hits record highs, Autoship is habitual replenishment of consumables rather than a discretionary monthly indulgence. The mechanism is simple: each customer who converts to Autoship re-orders on a fixed schedule at a modest discount, with no promotional friction driving the transaction. Over the FY2021-FY2025 arc, Autoship mix expanded every single year from 70.5% to 83.3% - even as active customer count went sideways post-COVID and NSPAC growth slowed. The 83% floor means approximately $10.4B of FY2025 revenue was contractually recurring before the year started. Source: 10-K FY2025.

2. The FCF inflection is real and structural. Free cash flow went from $8.6M (FY2021) to $119.3M (FY2022) to $342.9M (FY2023) to $452.5M (FY2024) to $562.4M (FY2025). This is operating cash flow ($691.6M) minus capex ($129.2M). It is not the product of one-time releases or accounting choices - it is Autoship mix lifting gross margin at 60bps per year while SG&A as a percentage of revenue declined from approximately 22% to 21.2%. The Q1 FY2026 adjusted EBITDA margin of 7.5% was the most profitable quarter in Chewy's history. Source: 10-K FY2025; Q1 FY2026 earnings release.

3. Pharmacy is the fastest-growing category and the highest-margin mix shift. Pet health and specialty products (which includes Chewy Pharmacy, CarePlus insurance, PracticeHub, and Chewy Vet Care) grew 11.8% in FY2025 to $1,980.5M (15.7% of revenue) and grew 13.3% in Q1 FY2026 to $562.7M (16.7% of Q1 revenue). Consumables, at 68.3% of Q1 mix, grew only 5.3%. Every percentage point of revenue that migrates from consumables to pharmacy and health services carries meaningfully higher gross margin. The 10-K FY2025 confirms Chewy operates the "#1 pet pharmacy in America" - a distribution moat that took a decade and regulatory complexity to build. Source: 10-K FY2025; Q1 FY2026 10-Q.

4. A debt-free balance sheet that has funded its own capital returns. As of February 1, 2026, Chewy carried zero funded debt - $0 drawn on its $800M ABL credit facility (matures April 2030, $783.1M available borrowing capacity), and $878.8M in cash and marketable securities. Over FY2024-FY2025, Chewy used its own FCF to repurchase $1.2B+ in shares directly from BC Partners, often at prices below market. That is not a company subsidizing growth with debt; it is a business monetizing its subscription cash flow to clear governance overhang at attractive prices. Source: 10-K FY2025 capital structure disclosures; edgar.json.

Section 4 - Weaknesses: the cracks in the 10-Q

1. NSPAC growth is decelerating and has no obvious re-acceleration lever. Net Sales Per Active Customer - the primary organic growth engine once the customer base is built - grew 15% in FY2022, 12% in FY2023, 4% in FY2024, and 2% in FY2025. Active customer growth in FY2025 was 4.0% YoY (21.327M). Simple arithmetic: 4% customer growth plus 2% NSPAC growth produces 6% revenue growth - exactly what FY2025 delivered. Management flagged on the June 10, 2026 Q1 FY2026 earnings call that they expected "a short-term NSPAC headwind as consumers become more discerning and deliberate in discretionary spending decisions" with "modest pressure on product attach rates and premiumization, particularly in discretionary categories." The Autoship subscription deepens spend per cohort, but at 83-84% mix the subscription ceiling is approaching and the incremental wallet expansion per customer is slowing - the same growth-deceleration problem, in a different shape, that Etsy's marketplace teardown lays out, where a slowing volume engine forces the business to lean harder on monetizing the existing base. Source: 10-K FY2025; Q1 FY2026 earnings call summary (Yahoo Finance, June 10, 2026).

2. Vet clinic capital is going in with no disclosed unit economics - and the bet just got much larger. The 10-K FY2025 discloses Chewy expanded from 8 to 18 Chewy Vet Care clinics during FY2025. Neither the 10-K nor any subsequent 10-Q discloses clinic-level revenue, margin, or payback period. Chewy has since made two post-FY2025 acquisitions: SmartPak Equine LLC ($175M cash, a leading provider of equine health and nutrition products, completed February 2, 2026 - one day after the FY2025 fiscal year-end) and Modern Animal ($400M cash, a technology-forward veterinary platform, closed May 21, 2026). Combined post-FY2025 M&A: $575M. Per management commentary on the Q1 FY2026 earnings call (June 10, 2026), the combined clinic target is approximately 60 locations by end of FY2026. The 10-K risk language is direct: "the development and expansion of Chewy Vet Care and other new services may increase our operating expenses and result in operating losses as we continue to expand our business." Competing against Banfield/PetSmart, BluePearl (Mars), VCA (Mars), and National Veterinary Associates - all established at scale - with no disclosed unit economics is the highest-risk capital allocation in Chewy's history. Source: 10-K FY2025 Item 1A; Q1 FY2026 10-Q Note 3 (SmartPak acquisition); Q1 FY2026 10-Q subsequent event disclosure (Modern Animal).

3. The FY2024 net income comparison will fool you - here is the correct baseline. FY2024 GAAP net income was $392.7M. FY2025 GAAP net income was $222.8M. That looks like a $169.9M decline. It is not. The FY2024 figure included a one-time $275.7M deferred tax asset valuation-allowance release - the monetization of historical net operating losses accumulated during Chewy's pre-profitability years (the GAAP income tax benefit line shows $241M, which is the $275.7M release net of ~$34.7M current tax expense). Adjusted net income in FY2024 was $446.8M; in FY2025 it was $540.5M - a $93.7M improvement. Operating income rose from $112.6M to $254.3M. FCF rose from $452.5M to $562.4M. The GAAP net income comparison misleads; the operating lines confirm a year of genuine improvement. Source: 10-K FY2025 Adjusted Net Income reconciliation (offset 235801).

4. BC Partners' controlled-company status and the dual-class discount are a structural valuation headwind. As of the May 13, 2026 proxy, BC Partners affiliates beneficially own 43.2% of outstanding shares but 88.4% of total voting power through 176.5M Class B shares (10 votes each). The 10-K FY2025 risk section states verbatim: "The dual class structure of our common stock may adversely affect the trading market for our Class A common stock" and "We are a 'controlled company' within the meaning of the rules of NYSE." CHWY is excluded from FTSE Russell indices as a result of the dual-class structure, mechanically limiting demand from passive index funds. BC Partners has been reducing its stake in an orderly way - Chewy repurchased $942.8M in FY2024 and $262.5M in FY2025 directly from BC Partners - but the overhang is not resolved with 176.5M Class B shares still outstanding. Source: 10-K FY2025 Item 1A; DEF 14A filed May 22, 2026.

Section 5 - Opportunities and threats

The opportunity set is the clearest it has been in Chewy's public history. The pharmacy and health platform is growing faster than the core consumables business, and the vet clinic strategy - if the unit economics prove out - creates a customer relationship depth that no online-only competitor can replicate. In-person vet visits generate prescription authority for the pharmacy, deepen Autoship attachment, and create a data asset around pet health that compounds over the pet's lifetime. The bull case is not "Chewy gets 10% more gross margin on food" - it is "Chewy becomes the vertically integrated pet health destination."

Canada is an underappreciated growth surface. The 10-K discloses Canadian operations as an emerging international expansion; if the Autoship mechanics translate, Canada represents a direct replication of the US playbook with less competitive pressure from Petco (which has minimal Canadian presence).

Sponsored advertising - digital ad placements sold to the same brand partners whose products Chewy sells - is a near-pure-margin revenue stream that is growing but not separately disclosed. At the $12.6B revenue scale, even a 1-2% advertising attach rate would generate $125-250M in high-margin revenue that does not carry the fulfillment cost of physical inventory.

The threat picture is concentrated in three areas. First, Amazon remains structurally better positioned on logistics speed and cost, and its Subscribe & Save program directly competes with Autoship at lower delivered cost on commodity consumables. The 10-K FY2025 names tariff risk explicitly: "A significant portion of our suppliers for our private brand business and our non-consumable business are located in China," and management guided in the Q1 FY2026 earnings call that Q2 FY2026 gross margin is expected to "contract modestly year-over-year" partly due to "elevated fuel surcharges from carrier partners." That would be the first year-over-year gross margin decline in several years. Source: 10-K FY2025 Item 1A; Q1 FY2026 earnings call.

Second, consumer discretionary pressure is arriving in the data. The APPA March 26, 2026 report puts US pet industry expenditure at $158B in 2025 (+3.7%) with roughly 2% of that growth inflation-driven - meaning real volume growth is approximately 1.7%. Chewy's 7.7% Q1 FY2026 growth rate is far ahead of category, but the management-disclosed NSPAC headwind from consumers becoming "more discerning" is a category-level signal, not a Chewy-specific one.

Third, the vet clinic expansion creates a capital and operational risk Chewy has not navigated before. Vet clinics are subject to state-by-state corporate practice of medicine regulations, require staffing at a veterinary labor market that is chronically undersupplied, and compete against chains with decades of operational history. The $575M in post-FY2025 acquisitions ($175M SmartPak Equine, February 2, 2026; $400M Modern Animal, May 21, 2026) compounds the capital commitment before the first generation of clinics has reported a full year of publicly disclosed results.

Section 6 - The macro environment

Chewy is flying through three macro forces simultaneously, two of which point in the same direction.

The pet-humanization trend is the structural long-term tailwind. The 2025 APPA survey counted approximately 94.2 million US households owning pets - a level that has been broadly stable since COVID-driven adoption. That adoption cohort is now in the pet ownership lifecycle stage where preventive care, premium nutrition, and specialty health products become the recurring spend. This is the demographic basis for pharmacy and vet care growth: older pets, wealthier pet owners, and the "pet parent" identity that drives premiumization. Chewy's own Year in Pets 2025 publication cited 21.2 million pet parents in its community, with dogs at 65% and cats at 32% of the species mix. Source: Chewy Year in Pets 2025, November 20, 2025.

Post-pandemic normalization is the counterforce on new-customer acquisition. Chewy's active customer count peaked at 20.663M in FY2021, fell to 20.083M by FY2023, partially recovered to 20.514M in FY2024, and reached 21.327M by FY2025. The initial COVID surge pulled forward 3-5 years of online pet adoption; the recovery has been gradual, and new customer acquisition is now roughly tracking category growth rather than outrunning it. The good news: the cohort that stayed after 2021 converted aggressively to Autoship, deepening per-customer spend. The constraint: incremental customer growth requires actual new US pet households, which is growing more slowly than the addressable-market assumptions underwriting growth expectations.

Consumer discretionary pressure is the third force and the most immediate. The Q1 FY2026 earnings call was notable for management's explicit acknowledgment of consumer spending caution in discretionary pet categories. Pet hardgoods (toys, beds, apparel) grew 15.4% in Q1 FY2026, but management flagged pressure on "premiumization" - the uptrading that drove the biggest NSPAC gains in earlier years. Fuel surcharges, tariff pass-through on China-sourced hardgoods, and the general consumer-confidence picture all work against the NSPAC growth that Chewy's revenue model depends on. Source: Q1 FY2026 earnings call summary; 10-K FY2025 tariff risk language.

Section 7 - The CFO verdict and the operator bridge

Here is the read on Chewy from a CFO's vantage point, engaging the Street's debate directly.

The bull thesis - Autoship as a durable subscription moat compounding toward a healthcare platform - is largely correct. 83.3% recurring mix, $562M FCF, and six consecutive years of gross margin expansion are not flukes. The unit economics of subscription e-commerce pet food at Chewy's scale are demonstrably sound; the losses of FY2021-FY2023 were SBC plus investment choices, not structural model failure. The 10-K arc confirms this: the profitability question was always answerable at scale, and Chewy answered it.

Where I disagree with the consensus is on what the next two years look like. The bull case on Street implies the vet clinic expansion is additive to the FCF story. I read it differently. Vet clinics are a capital-intensive format with unknown unit economics, competing against Mars, PetSmart/Banfield, and NVA - operators who have been at this for decades. The $575M in post-FY2025 acquisitions ($175M SmartPak Equine, equine health/nutrition, closed February 2, 2026; $400M Modern Animal, vet clinic platform, closed May 21, 2026 - both per the Q1 FY2026 10-Q) plus the planned 60-clinic buildout represent a capital deployment that exceeds Chewy's FY2025 FCF of $562.4M in a single year. The "build the data flywheel with clinic relationships" thesis is intellectually elegant. The question a CFO asks is: what is the clinic-level EBITDA, and at what clinic count does the aggregate vet care P&L become accretive to the consolidated margin? That number is not in any public filing.

The bear case - that NSPAC deceleration plus vet clinic capex will compress FCF - is worth taking seriously but is probably overstated. The pharmacy business is growing 13% and carrying margin well above consumables. Autoship at 84% is not collapsing. Even at 2% NSPAC growth and 4% customer growth, Chewy's revenue trajectory still supports $700M+ of adjusted EBITDA. The FCF ceiling concern is legitimate; it is not an existential one.

The differentiated Eightx read: the real risk is that management uses FCF to fund a new operating model (vet clinics) at the same time they are funding shareholder returns ($500M buyback authorization, April 2026). Research bundle notes indicate a $600M Term Loan B was launched post-period (not disclosed in the Q1 FY2026 10-Q itself; attributed to the April 8, 2026 8-K and earnings call commentary), marking the first time Chewy has actively sought debt for capital deployment. A company generating $562M in FCF that is also reported to be issuing a $600M term loan to "provide flexibility for shareholder returns and M&A" is telling you the capital demands exceed the organic cash generation. That is not disqualifying - but it changes the risk profile from "debt-free subscription retailer" to "selectively debt-financed platform builder."

The operator bridge. Your $5-80M brand almost certainly has a version of the Chewy pattern - smaller in magnitude, but structurally identical. The tell is this: you have a subscription or repeat-purchase mechanic that generates predictable revenue, and you are considering a capital investment in an adjacent format (a new channel, a new service, a physical location) that will be accretive in year three but dilutive to cash in year one and two.

The Chewy version of this is a $400M vet clinic acquisition. Your version might be a wholesale account that requires 90-day terms and $300K in upfront inventory, or a retail partnership that needs $150K of fixture investment before it generates a dollar of revenue. The subscription model is a wonderful thing to have - until you use it to subsidize a capital bet whose unit economics you haven't closed.

What I watch at Chewy every quarter is not the GAAP net income line - that number is polluted by SBC, DTA releases, and one-time items. I watch three things: (1) NSPAC dollar growth, because the model is mature enough that customer count is not the primary driver and wallet expansion is; (2) pet health and specialty revenue growth rate, because the pharmacy-to-clinic mix shift is the only legitimate gross margin expansion lever available to a pet-food retailer; and (3) whether vet clinic unit economics ever appear in a 10-K or investor day. The day they disclose clinic-level P&L is the day the vet bet becomes underwritable.

Early-warning scorecard - five lines that catch this 12 months early:

1. NSPAC year-over-year growth rate: if it drops below 2%, revenue growth has no organic engine beyond customer count, and customer count is growing at category rates (3-4%). Watch Q2-Q3 FY2026.
2. Pet health and specialty as a share of total revenue: currently 15.7% and growing. If this plateaus while consumables decelerates, the gross-margin expansion story runs out of fuel. The pharmacy attach rate is the canary.
3. Vet clinic unit economics disclosure: any investor day, 10-K, or press release that gives revenue per clinic or contribution margin per clinic. Absence of disclosure is itself a signal - at 60+ clinics with hundreds of millions deployed, continued silence on unit economics is unusual.
4. FCF conversion from adjusted EBITDA: in FY2025, $719M adj EBITDA produced $562M FCF - an 78% conversion rate. If that drops below 65% while adj EBITDA is growing, capex is absorbing the value creation. Watch the FY2026 capex guidance update.
5. BC Partners Class B share count: as of May 2026, 176.5M Class B shares remain. Each 10M-share block they exit adds Class A supply and reduces the voting control discount. The pace of resolution tells you whether the governance overhang clears in 2-3 years or 5-7.

If you want to run this scorecard against your own numbers before your equivalent of the vet clinic bet arrives, that is a fractional CFO conversation. The analysis takes a few hours. The cost of not doing it compounds every quarter you are deploying capital without a closed unit-economics thesis.

Related reading. For how the same pet-category math plays out at a DTC-native brand, see our Jinx teardown.

Related reading. For how the same pet-category math plays out at a diversified supplier, see our Central Garden & Pet teardown.

Sources and methodology

SEC EDGAR is the primary source for every financial figure in this post. Chewy, Inc. (CIK 0001766502) files on SEC EDGAR under 10-K and 10-Q form types. Specific filings used: 10-K FY2025 (filed 2026-03-25, accession 0001766502-26-000034); 10-Q Q1 FY2026 (filed 2026-06-10, accession 0001628280-26-042060); 10-K FY2024 (filed 2025-03-26, accession 0001766502-25-000014); 10-K FY2023 (filed 2024-03-20, accession 0001766502-24-000014); 10-K FY2022 (filed 2023-03-22, accession 0001766502-23-000011); 10-K FY2021 (filed 2022-03-29, accession 0001766502-22-000008). Revenue, gross margin, operating income, FCF, Autoship, NSPAC, active customers, and balance sheet figures are sourced directly from these filings and the edgar.json compiled from the SEC EDGAR MCP pull dated June 23, 2026. Where FY2021 and FY2022 gross margin and operating margin detail was not available in the XBRL pull, the figures are marked as estimated in the arc table.

The FY2024 DTA caveat is sourced directly to the 10-K FY2025 Adjusted Net Income reconciliation table (offset 235801): the deferred tax asset valuation allowance release line shows ($275.7M) for FY2024. The GAAP income tax benefit of ($241.0M) for FY2024 is a net figure - the $275.7M release less approximately $34.7M of current tax expense. This post uses $275.7M as the DTA release amount throughout; the $241M figure that appears in the EBITDA reconciliation table is the net income tax provision/benefit line, which is a different number. The FY2024 10-K filing (filed 2025-03-26) confirmed this as a one-time item; FY2025 10-K confirms the FY2025 adjusted net income of $540.5M. Every comparison of net income across FY2024 and FY2025 in this post uses the adjusted or operating-income basis, not GAAP net income.

Q1 FY2026 figures are sourced to the Chewy Q1 FY2026 earnings release (June 10, 2026, investor.chewy.com) and the 10-Q filed the same date. The SmartPak Equine LLC acquisition ($175M, equine health and nutrition, closed February 2, 2026) is disclosed in the Q1 FY2026 10-Q Note 3 (Acquisitions). The Modern Animal acquisition ($400M, closed May 21, 2026) is a subsequent event disclosed in the Q1 FY2026 10-Q. Combined post-FY2025 M&A: $575M. The clinic count target of approximately 60 by FY2026 year-end is from management commentary on the Q1 FY2026 earnings call (Yahoo Finance summary, June 10, 2026) and is not stated in any SEC filing.

BC Partners ownership and voting power are sourced to Chewy's DEF 14A filed May 22, 2026 (stockholder.net/CHWY). The figure of 88.4% voting power reflects 176,478,229 Class B shares (10 votes) alongside 232,505,429 Class A shares (1 vote) as of May 13, 2026 record date. The FTSE Russell exclusion for dual-class structures is a standard index rule, not a Chewy-specific filing disclosure.

The $600M Term Loan B is sourced to the research bundle (Parallel.ai) and the June 10, 2026 earnings call summary. It is not disclosed in the Q1 FY2026 10-Q (zero matches on "Term Loan" in that filing). The likely primary source is the April 8, 2026 8-K; this post attributes the Term Loan B to research bundle / earnings call commentary rather than the 10-Q. The "$500M repurchase authorization" (April 2026) is from the research bundle. These are post-FY2025-period-end items; the FY2025 10-K balance sheet itself showed $0 funded debt.

Petco gross margin comparison (38.0% FY2025) is sourced to Petco Health and Wellness Q4 and Full Year 2025 results (ir.petco.com, March 11, 2026) and macrotrends.net historical data. This is the most recent period-matched comparison available.

APPA pet industry expenditure data ($158B in 2025, +3.7%; $165B projected 2026, +4.4%) is sourced to the American Pet Products Association press release (americanpetproducts.org, March 26, 2026).

Social signal is colour only. The three TikTok embeds in Section 2 are from the Chewy demand culture and carry no financial claim. @jonathan.roehm (1.5M plays), @cam2rs.cats (391.8K plays, 24K likes), and @salemandharry (174.1K plays, 13.8K likes) were selected from the research bundle's tiktok_top5_embeds.json as illustrative of the Chewy Autoship consumer behavior and brand attachment. They are not evidence of any revenue or margin figure.

Limitations. Chewy does not disclose vet clinic-level revenue or unit economics; the vet care P&L analysis in this post is based on available filing language and publicly disclosed investment amounts, not internal models. The SmartPak Equine ($175M, Feb 2, 2026) and Modern Animal ($400M, May 21, 2026) acquisitions together total $575M in post-FY2025 M&A; both are disclosed in the Q1 FY2026 10-Q. The $600M Term Loan B is from research bundle / earnings call commentary and is not in the Q1 FY2026 10-Q. The clinic count target of approximately 60 by FY2026 year-end is from management commentary on the Q1 FY2026 earnings call (June 10, 2026) and is not stated in any SEC filing. This post reflects filings and disclosures current through June 23, 2026.

Frequently asked questions

is chewy actually profitable?

Yes - but the GAAP net income comparison across FY2024 and FY2025 misleads. FY2024 net income of $392.7M included a $275.7M one-time deferred tax asset valuation-allowance release (the GAAP income tax benefit line of $241M is a net figure reflecting the $275.7M release less ~$34.7M current tax expense). FY2025 GAAP net income of $222.8M is lower, but operating income rose from $112.6M to $254.3M, adjusted EBITDA from $570.5M to $719.2M, and free cash flow from $452.5M to $562.4M. The underlying profitability improved every year from FY2021 forward. Compare on FCF and operating income.

what is chewy autoship and why does it matter?

Autoship is Chewy's subscription program that auto-replenishes pet food, medications, and supplies on a customer-chosen schedule at a small discount. In FY2025, Autoship accounted for 83.3% of Chewy's $12.6B in net sales - up from 70.5% in FY2021. In Q1 FY2026, it reached 84.4%. That recurring mix makes Chewy's revenue more predictable than almost any other large online retailer. It also supports gross margin because Autoship orders carry less promotional discount than one-off transactional purchases. The subscription mechanic is Chewy's structural advantage and the primary reason the business generates $562M in FCF at a 2% GAAP operating margin.

what happened to chewy's net income from fy2024 to fy2025?

FY2025 GAAP net income ($222.8M) appears lower than FY2024 ($392.7M) but is not a deterioration. FY2024 net income was inflated by a one-time $275.7M deferred tax asset valuation-allowance release from historical net operating losses (the GAAP income tax benefit of $241M is this release net of current tax expense). Strip that out and FY2024 adjusted net income was $446.8M versus FY2025 adjusted net income of $540.5M. Operating income rose from $112.6M to $254.3M. Free cash flow rose from $452.5M to $562.4M. The business improved materially in FY2025; the GAAP net income line obscures it.

what is chewy vet care and what are the unit economics?

Chewy Vet Care is a chain of in-person veterinary clinics Chewy owns and operates, expanded from 8 clinics in FY2024 to 18 by the FY2025 fiscal year-end (February 1, 2026). Post-FY2025, Chewy made two acquisitions: SmartPak Equine LLC ($175M cash, equine health and nutrition, closed February 2, 2026 per Q1 FY2026 10-Q Note 3) and Modern Animal ($400M cash, a technology-forward veterinary platform, closed May 21, 2026 per Q1 FY2026 10-Q subsequent event). Per management commentary on the Q1 FY2026 earnings call (June 10, 2026), the combined vet clinic target is approximately 60 locations by end of FY2026 - a figure from earnings call commentary, not stated in any SEC filing. Clinic-level unit economics - revenue per clinic, contribution margin, payback period - are not disclosed in any SEC filing. The strategic thesis is that clinics deepen pharmacy and Autoship attachment and generate pet health data, but the P&L has not been tested at scale in a public format.

who controls chewy?

BC Partners, the private equity firm that acquired Chewy from PetSmart in 2017, retains voting control through 176.5M Class B shares (10 votes each) despite owning approximately 43.2% of economic shares. As of May 13, 2026, BC Partners affiliates hold 88.4% of total voting power. Chewy is classified as a "controlled company" under NYSE rules and is excluded from FTSE Russell indices due to the dual-class structure. BC Partners has been reducing its stake in an orderly way via secondary offerings and direct buybacks by Chewy ($1.2B+ repurchased directly from BC Partners in FY2024-FY2025), but the overhang is not fully resolved.

does chewy have debt?

As of February 1, 2026 (FY2025 fiscal year-end), Chewy carried no funded debt - zero drawn on its $800M ABL credit facility. Cash and marketable securities were $878.8M. Post-period, Chewy completed two acquisitions: SmartPak Equine ($175M, February 2, 2026) and Modern Animal ($400M, May 21, 2026), for $575M in total M&A. Research bundle notes and earnings call commentary indicate a $600M Term Loan B was also launched (not in the Q1 FY2026 10-Q; attributed to the April 2026 8-K and earnings call). The balance sheet is transitioning from debt-free to selectively debt-financed.

why is the nspac deceleration important to watch?

Net Sales Per Active Customer (NSPAC) is Chewy's primary organic growth engine at a subscription scale where acquiring new customers grows slowly. NSPAC grew 15% in FY2022, 12% in FY2023, 4% in FY2024, and 2% in FY2025. At 4% customer growth plus 2% NSPAC growth, Chewy can only grow revenue at roughly 6% - consistent with FY2025 results. If NSPAC growth continues decelerating, the revenue growth rate follows. Management flagged a "short-term NSPAC headwind" from consumers becoming more cautious on discretionary spending on the Q1 FY2026 earnings call (June 10, 2026). The pharmacy mix shift is the only lever that can organically re-accelerate NSPAC without new customer acquisition.

who are chewy's main competitors?

Chewy competes primarily with Amazon (Subscribe & Save for pet consumables, with structural logistics advantages), Petco (physical specialty retail at 38.0% gross margin but -2.5% revenue in FY2025), and PetSmart (private, physical retail). In vet care, the new competitive surface is Banfield/PetSmart, BluePearl (Mars), VCA (Mars), and National Veterinary Associates - all operators with decades of in-person veterinary experience. Chewy's moat versus Amazon is the 84% Autoship retention rate and the pharmacy/health platform depth. Its disadvantage versus Amazon is logistics speed and delivered cost on commodity consumables.